Agios Pharmaceuticals (AGIO) Retained Earnings: 2012-2025
Historic Retained Earnings for Agios Pharmaceuticals (AGIO) over the last 13 years, with Sep 2025 value amounting to -$453.7 million.
- Agios Pharmaceuticals' Retained Earnings fell 765.76% to -$453.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$453.7 million, marking a year-over-year decrease of 765.76%. This contributed to the annual value of -$148.9 million for FY2024, which is 81.90% up from last year.
- Per Agios Pharmaceuticals' latest filing, its Retained Earnings stood at -$453.7 million for Q3 2025, which was down 29.53% from -$350.2 million recorded in Q2 2025.
- Agios Pharmaceuticals' Retained Earnings' 5-year high stood at $30.9 million during Q1 2021, with a 5-year trough of -$1.0 billion in Q2 2024.
- For the 3-year period, Agios Pharmaceuticals' Retained Earnings averaged around -$534.9 million, with its median value being -$551.6 million (2023).
- Per our database at Business Quant, Agios Pharmaceuticals' Retained Earnings surged by 101.98% in 2021 and then plummeted by 1,181.15% in 2022.
- Agios Pharmaceuticals' Retained Earnings (Quarterly) stood at -$238.8 million in 2021, then crashed by 97.09% to -$470.6 million in 2022, then tumbled by 74.82% to -$822.6 million in 2023, then skyrocketed by 81.90% to -$148.9 million in 2024, then crashed by 765.76% to -$453.7 million in 2025.
- Its Retained Earnings was -$453.7 million in Q3 2025, compared to -$350.2 million in Q2 2025 and -$238.2 million in Q1 2025.